|Year : 2017 | Volume
| Issue : 1 | Page : 51
Assessing the need for routine screening for Mycoplasma genitalium in the low-risk female population: A prevalence and co-infection study on women from Croatia
Sunčanica Ljubin-Sternak1, Tomislav Meštrović2, Branko Kolarić3, Neda Jarža-Davila4, Tatjana Marijan4, Jasmina Vraneš1
1 Clinical Microbiology Department, Teaching Institute of Public Health “Dr. Andrija Štampar”; Medical Microbiology Department, School of Medicine, University of Zagreb, Zagreb, Croatia
2 Clinical Microbiology and Parasitology Unit, Polyclinic Dr. Zora Profozić", Zagreb, Croatia
3 Epidemiology Department, Teaching Institute of Public Health “Dr. Andrija Štampar”, Zagreb; Social Medicine and Epidemiology Department, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
4 Clinical Microbiology Department, Teaching Institute of Public Health “Dr. Andrija Štampar”, Zagreb, Croatia
|Date of Submission||02-Sep-2017|
|Date of Acceptance||02-Jun-2017|
|Date of Web Publication||04-Jul-2017|
Clinical Microbiology and Parasitology Unit, Polyclinic “Dr. Zora Profozić”, Bosutska 19
Source of Support: None, Conflict of Interest: None
Background: There is an ongoing debate regarding possible cost and benefits, but also harm of universal screening for the emerging sexually transmitted pathogen Mycoplasma genitalium. Methods: From the initial pool of 8665 samples that were tested, a subset of Chlamydia trachomatis-positive and randomly selected C. trachomatis-negative cervical swabs were further interrogated for M. genitalium by real-time polymerase chain reaction, using a 224 bp long fragment of the glyceraldehyde-3-phosphate dehydrogenase gene. Results: M. genitalium was detected in 4.8% of C. trachomatis-positive samples and none of C. trachomatis-negative samples. Accordingly, a significant association was shown between M. genitalium and C. trachomatis (P < 0.01), but also between M. genitalium and Mycoplasma hominis infection (P < 0.01). Conclusions: Based on the results, routine screening is recommended only for women with one or more identified risk factors. Moreover, younger age does not represent an appropriate inclusion/exclusion criterion for M. genitalium testing in the low-risk female population.
Keywords: Cervical swabs, Chlamydia trachomatis, Mycoplasma genitalium, Mycoplasma hominis, screening, sexually transmitted infections
|How to cite this article:|
Ljubin-Sternak S, Meštrović T, Kolarić B, Jarža-Davila N, Marijan T, Vraneš J. Assessing the need for routine screening for Mycoplasma genitalium in the low-risk female population: A prevalence and co-infection study on women from Croatia. Int J Prev Med 2017;8:51
|How to cite this URL:|
Ljubin-Sternak S, Meštrović T, Kolarić B, Jarža-Davila N, Marijan T, Vraneš J. Assessing the need for routine screening for Mycoplasma genitalium in the low-risk female population: A prevalence and co-infection study on women from Croatia. Int J Prev Med [serial online] 2017 [cited 2020 Aug 15];8:51. Available from: http://www.ijpvmjournal.net/text.asp?2017/8/1/51/209560
| Introduction|| |
Mycoplasma genitalium represents an emerging cause of sexually transmitted infections (STIs). It is considered as an independent risk factor for cervicitis in women, but its role in pelvic inflammatory disease, spontaneous abortion and infertility has not been ascertained until recently., The prevalence of M. genitalium in women ranges from <1% to 42%,, depending on whether we consider low-risk population (i.e., attendees of general practitioners and public health services) or high-risk population (i.e., sexually transmitted disease clinics attendees or those with specific symptoms).
There is an ongoing debate regarding possible cost and benefits, but also harm of universal screening for M. genitalium among low-risk individuals. Similar to many other countries, M. genitalium infection is not routinely screened for in Croatia and the data of its prevalence in the country are scarce – especially for the female population. Only one study regarding M. genitalium prevalence in Croatia was published thus far, conducted in men attending fertility clinic.
The aim of our study was therefore to determine the prevalence of M. genitalium in cervical swabs admitted to the public health laboratory, as well as to detect co-infection patterns of M. genitalium with Chlamydia trachomatis and other STIs in order to assess the necessity of implementing M. genitalium screening in the low-risk female population.
| Methods|| |
Swabs were taken from women with a low-risk for STIs, i.e., asymptomatic attendees of primary care gynecologist searching for screening and prenatal care. An unlinked anonymized method to test routinely collected and stored cervical swabs was used. The samples were collected at primary care and private gynecology offices in the Zagreb region, Croatia, and referred to the public health laboratory for routine C. trachomatis and genital Mycoplasma testing. Uniformity of samples collection was maintained by following the standard protocol and using collection kit comprised of dacron swab and MicroTest ™ M4RT ® transport medium (Remel Inc., Lenexa, USA). From the total pool of 8,665 samples collected from March 2014 to February 2015, 146 C. trachomatis positive and 168 randomly selected C. trachomatis negative samples were used in the study. Results for routinely tested genital Mycoplasma (Mycoplasma hominis and Ureaplasma spp.) were recorded prior to M. genitalium testing. The study was approved by the Ethics Committee of the institute where the research took place.
For C. trachomatis detection real-time polymerase chain reaction (PCR) was performed using Cobas ® Taqman ® CT v2.0 test on Cobas ® Taqman ® Analyzer (Roche Diagnostics GmbH, Mannheim, Germany). Identification of M. hominis and Ureaplasma spp. was performed by Mycoplasma IST 2 kit (bioMérieux SA, Lyon, France). M. genitalium was detected by real-time PCR LightMix ® kit Mycoplasma genitalium test (TIB MOLBIOL, GmbH, Berlin, Germany) on LightCycler 480 II Instrument (Roche Diagnostics GmbH, Mannheim, Germany), using a 224 bp long fragment of the glyceraldehyde-3-phosphate dehydrogenase gene. Difference between groups was assessed using Fisher's exact test and strength of association using univariate logistic regression when appropriate. Statistical analysis was performed using STATA/SE ver 11.2 (StataCorp LP, TX, USA).
| Results|| |
During 1 year period, in women who were using services of the public health laboratory, C. trachomatis prevalence of 1.9% (165/8665), M. hominis prevalence of 3.2% (277/8665), and Ureaplasma spp. prevalence of 33.3% (2885/8665) were observed. A total of 314 cervical swabs were further selected according to the C. trachomatis status (146 C. trachomatis positive and 168 C. trachomatis negative) and interrogated for M. genitalium. The additional analysis of selected samples on routinely tested genital mycoplasmas (M. hominis and U. urealyticum) revealed that 54 of 314 samples were M. hominis positive, and 181 of 314 were Ureaplasma spp. positive [Table 1]. C. trachomatis positive samples more commonly harbored routinely tested genital Mycoplasma in comparison to C. trachomatis negative samples (101/146; 69.2% vs. 72/168; 42.9% Fisher's exact P< 0.001).
|Table 1: Univariate associations between Mycoplasma genitalium infection and other bacterial sexually transmitted infections|
Click here to view
M. genitalium was detected in seven of 314 cervical swabs tested (2.2%, 95% confidence interval = 0.9%–4.5%). However, all positive samples for M. genitalium were also positive for C. trachomatis [Table 1]. Furthermore, five M. genitalium positive samples were detected in cervical swabs with initially proved triple infection (C. trachomatis, M. hominis and Ureaplasma spp.) and two M. genitalium positive specimens were detected in cervical swabs with initially proved dual infection. Eleven percent of those infected with M. hominis, 4.8% of those infected with C. trachomatis and 3.3% of those infected with Ureaplasma spp. were co-infected with M. genitalium. All selected samples negative to other sexually transmitted bacteria were also negative to the M. genitalium. Significant association was shown between M. genitalium and two bacterial STIs: C. trachomatis and M. hominis infection. There was no association between detection of M. genitalium and Ureaplasma spp. [Table 1]. The mean age of investigated women was 30.9 ± 9.9 years (age range: 1–69); women infected with tested bacteria (with the exception of those infected with M. genitalium) were significantly younger when compared to the uninfected women [Table 2].
|Table 2: Mean age of patients with and without detected sexually transmitted infections|
Click here to view
| Discussion|| |
Such low prevalence of M. genitalium on selected sample of low-risk female population tested for C. trachomatis is comparable to other published studies also conducted on cervical swabs tested for C. trachomatis. However, it seems that the true prevalence of M. genitalium in Croatian low-risk female population is substantially lower, since our study has found M. genitalium only in C. trachomatis positive samples. This presumptive, very low prevalence of M. genitalium infection in low-risk population of women in Croatia is concordant with reported prevalence of 0.8% in French women attending routine screening, but also with previous report of unusually low prevalence of M. genitalium detected in Croatian infertile men and their asymptomatic controls (1.4% and 0%, respectively). Present study also revealed that 4.8% of women with C. trachomatis and 11% of women with M. hominis also had M. genitalium infection, which is lower when compared to 9% of C. trachomatis-M. genitalium co-infected women that underwent population-based screening in London  and 11% in a screening study conducted in Norway.
The recommended treatment of uncomplicated C. trachomatis and M. genitalium infection is the same, but unlike C. trachomatis that does not show any homotypic resistance,M. genitalium has a high potential for developing resistance. This is the reason why the treatment of cervicitis or nongonoccocal urethritis should be based upon specific diagnostic testing, and a control PCR should be pursued 4–5 weeks after treatment. Moreover, since the therapy for C. trachomatis may not be effective for M. genitalium, the latter pathogen may represent a “Trojan horse” and hamper successful treatment, which is why it is significant to screen for co-infection.
At the moment, the decision to screen or not to screen is usually based on the discussion between health providers and patients (taking into account personal risk factors), especially aiming to test symptomatic women if molecular methods are available. Although recent meta-analysis has shown that testing high-risk symptomatic women on M. genitalium is warranted, our study suggest that in low-risk population it would be reasonable to implement M. genitalium screening only for those with proven risk factor such as C. trachomatis and/or M. hominis infection. Of course, acquiring precise insights into local M. genitalium epidemiology and tracking antimicrobial resistance development may represent a rationale to undertake screening endeavors regardless of the low prevalence of infection.
| Conclusions|| |
Other risk factors (i.e., multiple sexual partners, bacterial vaginosis, being symptomatic, smoking, prior miscarriage, black ethnicity, social class, marital status) including younger age are also associated with M. genitalium infection in the literature. Still, although this study demonstrated that women infected with M. genitalium were younger than woman without the infection, this was not statistically significant– hence younger age would not be an appropriate inclusion/exclusion criterion for M. genitalium screening in the low-risk population. In any case, further studies are needed to confirm or reject results of our investigation, especially those trying to elucidate the relationship between younger age and M. genitalium infection.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma genitalium
infections. J Eur Acad Dermatol Venereol 2016;30:1650-6.
Ljubin-Sternak S, Meštrovic T. Chlamydia trachomatis
and genital mycoplasmas: Pathogens with an impact on human reproductive health. J Pathog 2014;2014:183167.
Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium
infection and female reproductive tract disease: A meta-analysis. Clin Infect Dis 2015;61:418-26.
Rodrigues MM, Fernandes PÁ, Haddad JP, Paiva MC, Souza Mdo C, Andrade TC, et al.
Frequency of Chlamydia trachomatis
, Neisseria gonorrhoeae
, Mycoplasma genitalium, Mycoplasma hominis
species in cervical samples. J Obstet Gynaecol 2011;31:237-41.
Plecko V, Zele-Starcevic L, Tripkovic V, Skerlev M, Ljubojevic S, Plesko S, et al.
Unusually low prevalence of Mycoplasma genitalium
in urine samples from infertile men and healthy controls: A prevalence study. BMJ Open 2014;4:e005372.
Nilsen E, Vik E, Røed MA. Low prevalence of Mycoplasma genitalium
in patients examined for Chlamydia trachomatis
. Tidsskr Nor Laegeforen 2011;131:2232-4.
Peuchant O, Le Roy C, Desveaux C, Paris A, Asselineau J, Maldonado C, et al.
Screening for Chlamydia trachomatis
, Neisseria gonorrhoeae
, and Mycoplasma genitalium
should it be integrated into routine pregnancy care in French young pregnant women? Diagn Microbiol Infect Dis 2015;82:14-9.
Svenstrup HF, Dave SS, Carder C, Grant P, Morris-Jones S, Kidd M, et al.
A cross-sectional study of Mycoplasma genitalium
infection and correlates in women undergoing population-based screening or clinic-based testing for Chlamydia
infection in London. BMJ Open 2014;4:e003947.
Paulsen LK, Dahl ML, Skaare D, Grude N. Prevalence of M. genitalium
and U. urealyticum
in urine tested for C. trachomatis
. Tidsskr Nor Laegeforen 2016;136:121-5.
Ljubin-Sternak S, Mestrovic T, Vilibic-Cavlek T, Mlinaric-Galinovic G, Sviben M, Markotic A, et al
. In vitro
susceptibility of urogenital Chlamydia trachomatis
strains in a country with high azithromycin consumption rate. Folia Microbiol (Praha) 2013;58:361-5.
Plantamura J, Bigaillon C, Bousquet A, Delaune D, Larréché S, Bugier S, et al. Mycoplasma genitalium
: A mycoplasma still underestimated. Ann Biol Clin (Paris) 2017;75:209-14.
Short VL, Totten PA, Ness RB, Astete SG, Kelsey SF, Murray P, et al.
The demographic, sexual health and behavioural correlates of Mycoplasma genitalium
infection among women with clinically suspected pelvic inflammatory disease. Sex Transm Infect 2010;86:29-31.
[Table 1], [Table 2]
|This article has been cited by|
||Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016
| ||Jane Rowley,Stephen Vander Hoorn,Eline Korenromp,Nicola Low,Magnus Unemo,Laith J Abu-Raddad,R Matthew Chico,Alex Smolak,Lori Newman,Sami Gottlieb,Soe Soe Thwin,Nathalie Broutet,Melanie M Taylor |
| ||Bulletin of the World Health Organization. 2019; 97(8): 548 |
|[Pubmed] | [DOI]|
||Mycoplasma genitalium Coinfection in Women With Chlamydia trachomatis Infection
| ||Sally A. Harrison,Kristin M. Olson,Amy E. Ratliff,Li Xiao,Barbara Van Der Pol,Ken B. Waites,William M. Geisler |
| ||Sexually Transmitted Diseases. 2019; 46(10): e101 |
|[Pubmed] | [DOI]|